Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunogen Inc
< Previous
1
2
3
4
5
Next >
ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review
May 23, 2022
From
ImmunoGen
Via
Business Wire
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
May 10, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
May 06, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results
April 21, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference
March 31, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer
March 29, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting
March 19, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and 2021 Financial Results
February 25, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference
February 23, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
February 15, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
February 10, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference
February 04, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs
January 31, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference
December 29, 2021
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
December 12, 2021
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 06, 2021
From
ImmunoGen, Inc.
Via
Business Wire
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
December 10, 2021
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options...
Via
FinancialNewsMedia
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
December 02, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Proposed Public Offering of Common Stock
November 30, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
November 30, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
November 17, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
November 16, 2021
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
November 04, 2021
From
ImmunoGen
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.